منابع مشابه
Amyloid as a natural product
Amyloid fibrils, such as those found in Alzheimer's and the gelsolin amyloid diseases, result from the misassembly of peptides produced by either normal or aberrant intracellular proteolytic processing. A paper in this issue by Marks and colleagues (Berson et al., 2003) demonstrates that intra-melanosome fibrils are formed through normal biological proteolytic processing of an integral membrane...
متن کاملStructure-based discovery of natural-product-like TNF-α inhibitors.
Small but effective: two natural-product-like inhibitors of tumor necrosis factor α (TNF-α; represented in green in the picture) have been identified using structure-based virtual screening. These compounds represent only the third and fourth examples of direct targeting of TNF-α by a small molecule, and display potency comparable to that of the strongest TNF-α inhibitor reported to date.
متن کاملNatural product family 18 chitinase inhibitors.
Ole Andreas Andersen received hisM.Sc and Ph.D from theUniversity of Tromsø, Norway, in 1998 and 2003, respectively. His Ph.Dwork was supervised by Prof. Edward Hough and comprised crystallographic and biochemical studies on human phenylalanine hydroxylase. Andersen had a postdoctoral fellowship for one year at The Norwegian Structural Biology Centre in Tromsø under the supervision of Prof. Arn...
متن کاملStructure-Based Design of Non-Natural Amino Acid Inhibitors of Amyloid Fibrillation
Many globular and natively disordered proteins can convert into amyloid fibers. These fibers are associated with numerous pathologies1 as well as with normal cellular functions2,3, and frequently form during protein denaturation4,5. Inhibitors of pathological amyloid fibers could serve as leads for therapeutics, provided the inhibitors were specific enough to avoid interfering with normal proce...
متن کاملHigh-Throughput Screen of Natural Product Libraries for Hsp90 Inhibitors
Hsp90 has become the target of intensive investigation, as inhibition of its function has the ability to simultaneously incapacitate proteins that function in pathways that represent the six hallmarks of cancer. While a number of Hsp90 inhibitors have made it into clinical trials, a number of short-comings have been noted, such that the search continues for novel Hsp90 inhibitors with superior ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biochemical Pharmacology
سال: 2017
ISSN: 0006-2952
DOI: 10.1016/j.bcp.2017.04.004